https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-01 / 2018 Sep;10(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-01 / 2018 Sep;10(9)2018-09-01 00:00:002018-09-01 00:00:00Selenium, Selenoproteins, and Immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-29 / CNS Oncol 2018 07;7(3):CNS22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-29 / CNS Oncol 2018 07;7(3):CNS222018-08-29 00:00:002019-02-15 09:00:10Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-25 / Curr Oncol Rep 2018 08;20(10):80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-25 / Curr Oncol Rep 2018 08;20(10):802018-08-25 00:00:002018-08-25 00:00:00The Role of Oncolytic Viruses in the Treatment of Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-23 / Ann Res Hosp 2018 Aug;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-23 / Ann Res Hosp 2018 Aug;22018-08-23 00:00:002020-02-05 10:32:52Further clinical advancement of dendritic cell vaccination against ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-22 / Expert Rev Vaccines 2018 08;17(8):697-705
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-22 / Expert Rev Vaccines 2018 08;17(8):697-7052018-08-22 00:00:002019-02-15 08:35:59Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-22 / Cancer Immunol. Immunother. 2018 Nov;67(11):1777-1788
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-22 / Cancer Immunol. Immunother. 2018 Nov;67(11):1777-17882018-08-22 00:00:002019-03-25 10:40:24Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-16 / Int J Mol Sci 2018 Aug;19(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-16 / Int J Mol Sci 2018 Aug;19(8)2018-08-16 00:00:002019-02-15 08:35:50Enhancement of Radiation Effectiveness in Cervical Cancer Cells by Combining Ionizing Radiation with Hyperthermia and Molecular Targeting Agents
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-07 / Sci Rep 2018 Aug;8(1):11800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-07 / Sci Rep 2018 Aug;8(1):118002018-08-07 00:00:002018-08-07 00:00:00Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-05 / BMJ Open 2018 08;8(8):e021701
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-05 / BMJ Open 2018 08;8(8):e0217012018-08-05 00:00:002018-08-05 00:00:00Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-01 / Nat. Rev. Immunol. 2018 Aug;18(8):498-513
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-01 / Nat. Rev. Immunol. 2018 Aug;18(8):498-5132018-08-01 00:00:002019-02-15 09:23:18Integrating oncolytic viruses in combination cancer immunotherapy
